Trial Outcomes & Findings for Adipocytokines in Endometrial Cancer (NCT NCT04697264)

Adipocytokines in Endometrial Cancer

Correlation between circulating levels of these markers and demographic characteristics such as age, parity, smoking status, menopausal status, medication use, use of HRT or hormonal contraception, the prevalence of diabetes and hypertension, any prior significant medical history or history of cancer and family history of cancer.

Data on endometrial cancer histological characteristics, including grade, stage, histology, LVSI, MELF and MSI were collected from histology reports. Endometrial cancer grade is based on glandular organisation: Grade 1 (\<5% non-glandular), Grade 2 (6-50%), and Grade 3 (\>50% non-glandular). Staging reflects cancer spread, from localised to distant involvement. Type 1 (70-80%) is estrogen-related cancer usually endometrioid histology, while Type 2 (10-20%) arises from atrophic endometrium, of non-endometrioid histology. A lower grade and stage and type 1 histology is associated with better prognosis. LVSI, cancer in lymphatic/vascular spaces of the myometrium, is an independent risk factor for recurrence. MELF (microcystic, elongated, fragmented myometrial invasion) correlates with larger tumours, deeper invasion, and LVSI. MSI indicates DNA mismatch repair defects and is linked to advanced histological features, such as deep invasion and high-grade endometrial cancers.

Plasma levels of adiponectin will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.

Plasma levels of leptin, IGF1 and IGF2 will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.

Plasma levels of IL6 and TNFα will be measured by ELISA in both the study and the control populations, and the results compared using linear regression tests.

Correlation between the markers and patients' obesity status using WHO BMI subgroups.

Correlation between the markers and patients' obesity status using WHO BMI subgroups.

Levels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.

Levels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.

Levels of biomarkers were assessed at baseline, at day 1, and at 6 months post-surgery in endometrial cancer patients (study population). To assess the effect of treatment i.e. surgery +/- adjuvant treatment on the levels of the biomarkers, associations were sought between the levels of biomarkers before surgery (day 0) and 6 months post-surgery and the results have been presented here.

Expression of adiponectin, leptin, and their receptors were studied in endometrial cancer tissue and fat tissue using qRT-PCR. Fresh endometrial tissue was collected from 39 endometrial cancer and 5 control patients. Fresh adipose tissue was collected from these 39 endometrial cancer patients. Normal endometrium was used as a reference (calibrator sample) and the expressions of the biomarkers were calculated as fold changes compared to the expression in the calibrator sample using the delta-delta Ct formula. A higher fold change indicates greater expression of the marker in the study sample compared to the benign calibrator sample. This allowed for a standardised comparison of biomarker expression across different tissues, such as cancerous and adipose tissues.

The expression of adiponectin and leptin and their receptors were studied in endometrial cancer tissue and lymph node tissue using qRT-PCR. 12 FFPE lymph nodal tissue blocks were collected from patients with lymph node dissection. Fresh endometrial tissue was collected from 39 endometrial cancer and 5 control patients, however, the data for the 12 patients with lymph node dissection is presented here. Normal endometrium was used as a reference (calibrator sample) and the expressions of the biomarkers were calculated as fold changes compared to the expression in the calibrator sample using the delta-delta Ct formula. A higher fold change indicates greater expression of the marker in the study sample compared to the benign calibrator sample. This allowed for a standardised comparison of biomarker expression across different tissues, such as cancerous and lymph nodal tissue.

Correlation between circulating adiponectin levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.

Correlation between circulating leptin, IGF1 and IGF2 levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.

Correlation between circulating IL6 and TNF levels (measured by ELISA) and their expression in endometrial tissue (measured by PCR). This was done for the 39 patients from whom we received the tissue sample.